Prognostic value of transglutaminase 2 in non-small cell lung cancer patients
PDF | HTML | How to cite
Metrics: PDF 1341 views | HTML 2138 views | ?
Zhu Chihong1,*, Ling Yutian1,*, Wan Danying1, Jiang Ruibin1, Sheng Huaying1, Gu Linhui1,2 and Feng Jianguo1,2
1Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China
2Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Hangzhou, Zhejiang 310022, China
*These authors have contributed equally to this work
Gu Linhui, email: [email protected]
Feng Jianguo, email: [email protected]
Keywords: TG2, NSCLC, prognosis
Abbreviations: TG2: Transglutaminase 2; NSCLC: non-small cell lung cancer
Received: November 23, 2016 Accepted: February 20, 2017 Published: April 24, 2017
Transglutaminase 2 (TG2) plays important roles in cell survival and cancer progression. In this study, we examined TG2 expression in specimen of 194 patients diagnosed with non-small cell lung cancer (NSCLC), and found that the TG2 gene expression was significantly higher in lung cancer tissues as compared to paired incisal marginal tissues or normal tissues. Our data revealed that patients with lower level of TG2 expression detected in cancer tissues had longer disease free survival and overall survival as compared to the patients with higher TG2 expression. We also found that TG2 expression level correlated to NSCLC recurrence. These results suggest a potential prognosis impact of TG2 for NSCLC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.